[go: up one dir, main page]

WO2006089150A3 - Agents anti-angiogeniques comportant de l'aldesleukine - Google Patents

Agents anti-angiogeniques comportant de l'aldesleukine Download PDF

Info

Publication number
WO2006089150A3
WO2006089150A3 PCT/US2006/005720 US2006005720W WO2006089150A3 WO 2006089150 A3 WO2006089150 A3 WO 2006089150A3 US 2006005720 W US2006005720 W US 2006005720W WO 2006089150 A3 WO2006089150 A3 WO 2006089150A3
Authority
WO
WIPO (PCT)
Prior art keywords
aldesleukin
antiangiogenic agents
compositions
antiangiogenic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/005720
Other languages
English (en)
Other versions
WO2006089150A2 (fr
Inventor
Sharon Lea Aukerman
Kimberly Denis-Mize
Laurence Elias
Bahija Jallal
Daniel Menezes
Gary W Witherell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to BRPI0608880-5A priority Critical patent/BRPI0608880A2/pt
Priority to JP2007556337A priority patent/JP2008530239A/ja
Priority to CA002598448A priority patent/CA2598448A1/fr
Priority to AU2006214138A priority patent/AU2006214138A1/en
Priority to EP06735400A priority patent/EP1853302A2/fr
Priority to MX2007010037A priority patent/MX2007010037A/es
Publication of WO2006089150A2 publication Critical patent/WO2006089150A2/fr
Publication of WO2006089150A3 publication Critical patent/WO2006089150A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une polythérapie faisant appel à des compositions IL-2 et à des agents anti-angiogéniques pour traiter le cancer. En outre, l'invention concerne des méthodes de réduction de toxicités et d'augmentation d'efficacité associées à l'administration de compositions de IL-2 ou de compositions anti-angiogéniques.
PCT/US2006/005720 2005-02-18 2006-02-17 Agents anti-angiogeniques comportant de l'aldesleukine Ceased WO2006089150A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0608880-5A BRPI0608880A2 (pt) 2005-02-18 2006-02-17 agentes anti-angiogênicos com aldesleucina
JP2007556337A JP2008530239A (ja) 2005-02-18 2006-02-17 アルデスロイキンを含む抗血管形成性剤
CA002598448A CA2598448A1 (fr) 2005-02-18 2006-02-17 Agents anti-angiogeniques comportant de l'aldesleukine
AU2006214138A AU2006214138A1 (en) 2005-02-18 2006-02-17 Antiangiogenic agents with aldesleukin
EP06735400A EP1853302A2 (fr) 2005-02-18 2006-02-17 Agents anti-angiogeniques comportant de l'aldesleukine
MX2007010037A MX2007010037A (es) 2005-02-18 2006-02-17 Agentes antiangiogenicos con aldesleucina.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65434105P 2005-02-18 2005-02-18
US60/654,341 2005-02-18

Publications (2)

Publication Number Publication Date
WO2006089150A2 WO2006089150A2 (fr) 2006-08-24
WO2006089150A3 true WO2006089150A3 (fr) 2006-11-02

Family

ID=36569884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/005720 Ceased WO2006089150A2 (fr) 2005-02-18 2006-02-17 Agents anti-angiogeniques comportant de l'aldesleukine

Country Status (10)

Country Link
EP (1) EP1853302A2 (fr)
JP (1) JP2008530239A (fr)
KR (1) KR20070108909A (fr)
CN (1) CN101146549A (fr)
AU (1) AU2006214138A1 (fr)
BR (1) BRPI0608880A2 (fr)
CA (1) CA2598448A1 (fr)
MX (1) MX2007010037A (fr)
RU (1) RU2007134570A (fr)
WO (1) WO2006089150A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101497607B (zh) * 2008-01-29 2012-11-28 上海百灵医药科技有限公司 舒尼替尼的合成方法
EP2149565A1 (fr) * 2008-07-24 2010-02-03 Bayer Schering Pharma AG Dérivés de chinazoline substitués par du sulfonamide en tant que modulateurs d'immunité pour le traitement de inflammations et allergies
EA201391720A1 (ru) * 2008-11-14 2014-04-30 Консерт Фармасьютикалс Инк. Замещенные диоксопиперидинилфталимидные производные
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
PT3575288T (pt) 2009-09-03 2021-12-09 Bristol Myers Squibb Co Quinazolinas como inibidores dos canais iónicos de potássio
WO2012079075A1 (fr) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Dérivés de phtalimide deutérés
WO2013130849A1 (fr) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Dérivés de phthalimide dioxopipéridinyle substitués
EP2838879A1 (fr) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Rigosertib deutéré
WO2014022728A1 (fr) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Dérivés 5-(quinazolin-2-yl)pyrimidin-2-amines substitués utiles comme inhibiteurs de pi3k/mtor pour le traitement du cancer
WO2014066243A1 (fr) 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Formes solides de {s-3-(4-amino-1-oxo-isoindolin-2yl)(pipéridine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (fr) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Dérivés substitués de dioxopipéridinyl phtalimide
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
CN105189462B (zh) 2013-02-20 2017-11-10 卡拉制药公司 治疗性化合物和其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2014170910A1 (fr) 2013-04-04 2014-10-23 Natco Pharma Limited Procédé de préparation du lapatinib
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR101478925B1 (ko) * 2013-12-31 2015-01-08 아주대학교산학협력단 프로테아좀 저해제와 로페라마이드를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
CA3036340A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
WO2018048746A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
CA3036336A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
CN108069913B (zh) * 2016-11-18 2022-03-01 陕西师范大学 双(吗啉基烷氧基)喹唑啉衍生物及其在抗肿瘤方面的用途
JP2020520665A (ja) 2017-05-24 2020-07-16 ノバルティス アーゲー 抗体−サイトカイングラフト化タンパク質及び癌の治療における使用方法
WO2020102195A1 (fr) 2018-11-13 2020-05-22 Biotheryx, Inc. Isoindolinones substituées
CN112300082B (zh) * 2019-07-26 2022-04-26 暨南大学 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
CN111499583B (zh) * 2020-05-22 2022-02-15 沈阳工业大学 喹唑啉衍生物及其作为抗肿瘤药物的应用
CN112538071A (zh) * 2020-11-30 2021-03-23 新乡医学院第一附属医院 用作raf-1抑制剂的化合物、制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SONI SANDEEP ET AL: "Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide.", JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY. 2002 AUG-SEP, vol. 24, no. 6, August 2002 (2002-08-01), pages 488 - 491, XP009067555, ISSN: 1077-4114 *
STERNBERG C N: "Metastatic renal cell cancer treatments.", DRUGS OF TODAY, vol. 39, no. Suppl. C, November 2003 (2003-11-01), pages 39 - 59, XP009067549, ISSN: 0025-7656 *

Also Published As

Publication number Publication date
RU2007134570A (ru) 2009-03-27
MX2007010037A (es) 2008-02-15
AU2006214138A1 (en) 2006-08-24
CA2598448A1 (fr) 2006-08-24
WO2006089150A2 (fr) 2006-08-24
EP1853302A2 (fr) 2007-11-14
KR20070108909A (ko) 2007-11-13
CN101146549A (zh) 2008-03-19
JP2008530239A (ja) 2008-08-07
BRPI0608880A2 (pt) 2010-02-02

Similar Documents

Publication Publication Date Title
WO2006089150A3 (fr) Agents anti-angiogeniques comportant de l'aldesleukine
IL257622B (en) Methods and preparations for the treatment of persistent infections
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
WO2008021368A3 (fr) Compositions et méthodes de neuroprotection
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
PL1765391T3 (pl) Kompozycje bakteryjne do leczenia nowotworów
WO2005094376A3 (fr) Methodes et compositions synergetiques utilisees dans le traitement du cancer
WO2008070041A3 (fr) Inhibiteurs de l'activité akt
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
WO2004075832A3 (fr) Methodes et compositions de traitement de douleurs chroniques au moyen de la dhea et de derives de celle-ci
WO2007011962A3 (fr) Traitement du cancer
WO2005105113A3 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
WO2007059108A3 (fr) Quinolones substituees et procedes d'utilisation
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2006024018A3 (fr) Methodes et compositions pour le traitement de la douleur nociceptive
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
WO2005004808A3 (fr) Composes tetracycliques utilises comme inhibiteurs de c-met
EP2425874A3 (fr) Utilisation de la vitamine D et un agent thérapeutique supplémentaire pour le traitment du cancer
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2006110638A3 (fr) Inhibiteur de l'activite akt
WO2007081751A9 (fr) Compositions et procedes destines au traitement du cancer
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
IL187405A0 (en) Methods and compositions for the treatment of pain

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680009316.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2598448

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010037

Country of ref document: MX

Ref document number: 2007556337

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006214138

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3324/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006214138

Country of ref document: AU

Date of ref document: 20060217

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077021118

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006735400

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007134570

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0608880

Country of ref document: BR

Kind code of ref document: A2